First Citizens Bank & Trust Co. Purchases 253 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

First Citizens Bank & Trust Co. grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 15,275 shares of the biopharmaceutical company’s stock after acquiring an additional 253 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in Gilead Sciences were worth $1,281,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. Blue Trust Inc. raised its stake in shares of Gilead Sciences by 38.4% in the third quarter. Blue Trust Inc. now owns 6,520 shares of the biopharmaceutical company’s stock worth $547,000 after purchasing an additional 1,808 shares during the last quarter. Capital Investment Advisors LLC grew its position in shares of Gilead Sciences by 10.8% during the 3rd quarter. Capital Investment Advisors LLC now owns 377,701 shares of the biopharmaceutical company’s stock valued at $31,666,000 after acquiring an additional 36,838 shares during the period. Moss Adams Wealth Advisors LLC purchased a new stake in shares of Gilead Sciences in the third quarter valued at approximately $215,000. Net Worth Advisory Group purchased a new stake in shares of Gilead Sciences during the third quarter worth about $743,000. Finally, Stratos Wealth Partners LTD. raised its holdings in shares of Gilead Sciences by 0.9% during the third quarter. Stratos Wealth Partners LTD. now owns 114,518 shares of the biopharmaceutical company’s stock valued at $9,601,000 after acquiring an additional 1,009 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 0.7 %

Shares of GILD stock opened at $86.72 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. The stock has a 50-day simple moving average of $81.06 and a 200 day simple moving average of $72.81. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86. The stock has a market capitalization of $108.04 billion, a P/E ratio of 240.89, a P/E/G ratio of 2.98 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The business had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were paid a $0.77 dividend. The ex-dividend date was Friday, September 13th. This represents a $3.08 annualized dividend and a yield of 3.55%. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now directly owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 36,847 shares of company stock valued at $3,033,340. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have recently weighed in on GILD. Wells Fargo & Company upgraded Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $78.00 to $100.00 in a report on Monday, October 7th. Barclays raised their price target on Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Truist Financial lifted their price objective on Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Finally, Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Ten equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $86.37.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.